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Abstract
Immunotherapy is a mainstay of treatment for nonesmall-cell lung cancer. Serious immune-related adverse
events (irAEs) occur; however, their effect on survival is unclear, and no defined risks factors have been
elucidated. In the present study, we found no significant effect of irAE on survival in a landmark analysis, and no
increased risk of pneumonitis in patients with previous radiation.
Background: The risk factors for immune-related adverse events (irAEs) remain undefined. Recently, a correlation
between irAEs and clinical benefit was suggested. We examined the risk factors for irAEs and their effect on survival in
patients with nonesmall-cell lung cancer (NSCLC) who had received immunotherapy. Patients and Methods: We
performed a retrospective review of patients with NSCLC treated with single-agent immunotherapy at our institution.
irAEs were determined by treating physician diagnosis. A landmark analysis was performed at 3 months using log-rank
tests and the Bonferroni method. Results: irAEs occurred in 27 of 91 patients (30%). The median overall survival (OS)
for patients with irAEs was longer than that for patients without (24.3 vs. 5.3 months; hazard ratio, 2.75; 95% con-
fidence interval, 1.54-4.92; P < .001). However, a landmark analysis of patients after 3 months of treatment revealed
no difference in OS between patients with and without irAEs. No increased risk of pneumonitis was seen in patients
with previous thoracic radiotherapy, although these patients had shorter survival (4.2 vs. 9.7 months; P ¼ .004).
Radiotherapy after the initiation of immunotherapy (n ¼ 15) did not increase the risk of irAEs or pneumonitis; however,
these patients had improved OS (17.3 vs. 6.0 months; P ¼ .016). Conclusion: The development of irAEs did not
significantly correlate with survival when controlling for the duration of therapy in a landmark analysis. We found no
increased risk of pneumonitis or irAEs in patients who had received radiotherapy. Radiotherapy before immunotherapy
was associated with shorter survival, and radiotherapy after immunotherapy was associated with improved survival.
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Introduction
Recent studies of immune checkpoint inhibitors (ICIs) have
demonstrated dramatic improvement in outcomes for select patients
with metastatic nonesmall-cell lung cancer (NSCLC).1-3 Overall,
these treatments have been well tolerated; however, serious immune-
related adverse events (irAEs) can occur,4 including pneumonitis, co-
litis, and hepatitis. The reported incidence of irAEs in clinical trials has
been relatively low; however, rare fatal events have been reported.5,6
The effect of irAEs on survival of patients with NSCLC is un-
certain. In melanoma, irAEs appear to be more likely in patients
who will derive clinical benefit from treatment with ICIs.7,8 Recent
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data have emerged for NSCLC; however, the findings have not been
uniform. One retrospective study of 71 patients with NSCLC
reported an association between overall response rate and irAEs
(P ¼ .007) but not OS (P ¼ .827).9 Another report of 51 patients
treated with pembrolizumab in the KEYNOTE-001 trial [study of
pembrolizumab (MK-3475) in participants with progressive locally
advanced or metastatic carcinoma, melanoma, or non-small cell
lung carcinoma (P07990/MK-3475-001/KEYNOTE-001)] found
that thyroid dysfunction occurring during treatment was associated
with improvement in OS (hazard ratio, 0.29; 95% confidence in-
terval [CI], 0.09-0.94; P ¼ .04) but not progression-free survival
(PFS).10 A multi-institution retrospective study of 134 patients with
NSCLC found an association at 6 weeks between the occurrence of
irAEs and both PFS and OS in a landmark analysis.11 A prospective
study of 43 patients found that the early occurrence of irAEs was
associated with a better disease control rate and PFS but not the
response rate or OS.12 These discrepant results between the devel-
opment of irAEs and the effect on the disease response rate, PFS,
and OS warrant further investigation.
The development of predictive biomarkers for serious irAEs
would aid patient selection for treatment plans that minimize the
risk of toxicities. Cancer-associated inflammation has long been
recognized as having a profound effect on survival,13 and markers of
systemic inflammation such as the neutrophil/lymphocyte ratio
(NLR) have been found to be prognostic in large meta-analyses of
all cancers14 and NSCLC.15,16 However, the ability of baseline
markers of systemic inflammation, including the NLR, platelet/
lymphocyte ratio (PLR),17,18 and advanced lung cancer inflamma-
tion index (ALI),19,20 to predict irAEs has not been assessed.
In the present study, we report the outcomes of 91 patients
treated with ICIs for NSCLC, with a specific focus on the devel-
opment of irAEs, their correlation with survival, an assessment of
the risk factors for irAEs, and the predictors of benefit from treat-
ment with ICIs.
Patients and Methods
A retrospective review of patients with NSCLC treated with a
single-agent ICI from September 2014 to June 2016 was per-
formed at The Ohio State University Comprehensive Cancer
Center. Consecutive patients with metastatic NSCLC who
received treatment either in clinical trial or with standard of care
at our institution were included in the present study. The
baseline patient characteristics were assessed from the physician
clinical care documentation and the electronic medical records.
irAEs were identified by diagnosis, attribution, and clinical
intervention (requiring either withholding treatment or new
treatment, whether topical or systemic, for the irAE). The irAEs
were graded using the Common Terminology Criteria for
Adverse Events, version 4.0. OS was calculated from the date of
the initiation of the ICI to death from any cause or the date of
the last follow-up examination. Patients with active malignancies
other than NSCLC were excluded. Patients who had received an
ICI in combination with either other immunotherapy or
chemotherapy were also excluded from the present analysis. The
institutional review board of The Ohio State University Medical
Center approved the present study.
Statistical Analysis
The patient demographic data and characteristics were summa-
rized using descriptive statistics (median and range for continuous
outcomes and frequency for discrete outcomes). OS was calculated
from the date of treatment initiation to death from any cause.
Patients who were still alive were censored at the last follow-up
examination. Survival curves were estimated using the Kaplan-
Meier method. OS was compared between patients with and
without serious irAEs using the log-rank test. The estimated median
with 95% CIs are reported in tabular format. OS was also compared
with the other patient demographic data and tumor characteristics
using a log-rank test or Cox regression model. In a landmark
analysis, patients were categorized into 4 groups according to
whether they had received ICI for > 3 months and whether they
had experienced irAEs. OS was compared among the groups using
log-rank tests, and the Bonferroni method was used to adjust for
multiple comparisons. The association of the incidence of irAEs and
pneumonitis with the patient and tumor characteristics has been
studied using the c2 test or Fisher’s exact test for categorical char-
acteristics and the logistic regression model for continuous charac-
teristics. The P values were adjusted for multiple comparisons using
the Bonferroni method, as needed. P values < .05 were considered
to indicate statistical significance. All analyses were conducted using
SAS, version 9.4 (SAS Institute, Cary, NC).
Inflammatory Markers
The NLR was calculated at baseline as the ratio of absolute
neutrophils to lymphocytes. An elevated NLR was defined as  5,
as previously described.14,15,21 The ALI was calculated as described
previously (body mass index  serum albumin/NLR), and values
of  18 were considered elevated.20 The PLR was calculated as the
ratio of platelets to absolute lymphocytes and was considered
elevated if > 237 (median PLR).17,18 Tumor mutation data were
obtained as the routine standard of care at our Clinical Laboratory




The characteristics of the 91 included patients are listed in
Table 1. The median patient age at immunotherapy was 67 years
(range, 40-87 years). The gender was relatively evenly split between
male and female (52% women). Nearly all patients received nivo-
lumab (n ¼ 88; 97%). The median line of therapy was 2 (range,
1-8). Of the 91 patients, 26 (29%) had been treated in the setting of
a clinical trial.
Occurrence of irAEs
Twenty-seven patients (30%) developed  1 irAE. The details of
the individual irAEs are listed in Table 2. The median time to onset
of irAEs was 3 months (range, 0.4-41.9 months; Figure 1). Patients
treated in a clinical trial had a greater rate of irAEs (53.9% vs. 20%;
P ¼ .001). For patients with immune-related pneumonitis (n ¼ 9;
10%), the median time to onset was 1.6 months (range, 0.4-11.4
months). Eight of these patients were treated with steroids, and only
1 patient was rechallenged with ICI. Three patients (3%) developed
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colitis; all required steroids. Three patients experienced multiple
irAEs. The other irAEs included dermatologic events (n ¼ 6),
thyroid dysfunction (hypothyroidism, n ¼ 6; thyrotoxicosis, n ¼ 1),
autoimmune insulin-dependent diabetes mellitus (n ¼ 1), hepatitis
(n ¼ 1), and pancreatic insufficiency (n ¼ 1).
Risk Factors for Development of irAEs
Data from the patient and tumor characteristics were assessed to
identify potential risk factors for the occurrence of irAEs overall
(Table 3) and for pneumonitis specifically (Table 4). A positive
smoking history was not associated with an increased risk of irAEs in
general (P ¼ 1.00) or pneumonitis specifically (P ¼ 1.00). The
histologic type (squamous vs. nonsquamous) also was not associated
with an increased risk of irAEs (P ¼ 1.00). The incidence of irAEs
was not affected by age (P ¼ .71). The Eastern Cooperative
Oncology Group performance status at treatment was also not
associated with the development of irAEs (P ¼ .25).
Data from tumor mutation analysis were available for 72 patients
(55 with nonsquamous, 14 with squamous, and 3 with adenosqu-
amous). The most commonly identified alteration was TP53 (n ¼
37; 41%), followed by KRAS mutations (n ¼ 26; 29%; Table 1).
Although not statistically significant, fewer irAEs developed in pa-
tients with KRAS-mutated tumors than in those with KRAS wild-
type tumors (P ¼ .059). A similar trend was observed in patients
with tumors harboring TP53 mutations (P ¼ .063).
All patients had undergone baseline laboratory testing before
starting treatment with immunotherapy, and the NLR, PLR, and
ALI were calculated to determine whether these indexes of
inflammation correlated with an increased risk of irAEs. An NLR 
5 was not associated with an increase in irAEs overall (P ¼ .94) or
pneumonitis specifically (P ¼ .18). An elevated PLR also did not
correlate with the occurrence of irAEs (P ¼ .45) or pneumonitis
(P ¼ .74), and an elevated ALI also was not associated with irAEs
(P ¼ .80) or pneumonitis (P ¼ .17).
Radiotherapy, irAEs, and Survival
Of the 91 patients, 28 (31%) had received previous chest
radiotherapy (RT) or thoracic RT (TRT) before receiving immu-
notherapy. The median time between TRT completion and ICI
therapy was 8.7 months (range, 0.4-34.7 months). Overall, no
increased risk of irAEs (P ¼ .81) or pneumonitis (P ¼ .13) was
found patients who had received previous TRT, and the timing of










Nonsquamous cell carcinoma 58 (64)























Data presented as n (%).
Abbreviation: ECOG ¼ Eastern Cooperative Oncology Group.
Table 2 Incidence and Severity of Immune-related Adverse Events
Toxicity All Grades (n, %) Grade 1-2 Grade ‡ 3 Rechallenge Systemic Steroid Use
Any irAE 27 (30) 21 (23) 6 (7) 16 (60) 13 (48)
Pneumonitis 9 (10) 5 (6) 4 (4)a 1 (11) 8 (89)
Dermatologicb 6 (7) 6 (7) 0 (0) 6 (100) 0 (0)
Endocrinec 7 (8) 6 (7) 1 (1) 5 (83) 0 (0)
Colitis 3 (3) 2 (2) 1 (1) 2 (67) 3 (100)
Hepatitis 1 (1) 0 (0) 1 (1) 1 (100) 1 (100)
Pancreatic insufficiency 1 (1) 1 (1) 0 (0) 1 (100) 0 (0)
aOne possible grade 5 pneumonitis developed in 1 patient with underlying lung disease with previous pneumonectomy, concern for pneumonia (sputum culture positive for Serratia marcescens and
Candida) or aspiration; the patient was transitioned to comfort care after no improvement with steroids, broad-spectrum antibiotics, and noninvasive positive-pressure ventilator support.
bIncluded 1 case of palmar-plantar erythrodysesthesia syndrome.
cIncluded 6 cases of hypothyroid and 1 case of Graves thyroiditis treated with methimazole.
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previous TRT did not affect the occurrence of irAEs overall (P ¼
.252) or pneumonitis, in particular (P ¼ .321). Thirty-six patients
had received nonecentral nervous system RT (including TRT)
before ICI treatment (median, 5.7 months; range, 0.2-47.3
months), and 15 patients had received RT after beginning ICI
therapy (median, 3.9 months; range, 1-18.8 months). RT before
immunotherapy was not associated with an increased risk of irAEs
(P ¼ .54) or pneumonitis (P ¼ .48). Also, RT after the initiation of
immunotherapy was not associated with a significantly increased
risk of irAEs (P ¼ .059) or pneumonitis (P ¼ .17). However, given
these small numbers, this finding should be interpreted with
caution. The timing of RT after ICI therapy was not significantly
associated with OS (P ¼ .120; Cox regression model). Unlike
previous studies, patients who received RT before ICI therapy had
shorter OS (median, 4.2 months; 95% CI, 2.4-8.1 months) than
that of the patients without previous RT (median, 9.7 months; 95%
CI, 6.5-19.4 months; P ¼ .004). However, the 15 patients who had
received RT after the initiation of immunotherapy had improved
OS (median, 17.3 months; 95% CI, 6.5 months to not reached
[NR]) compared with those without RT after the initiation of
immunotherapy (median, 6.0 months; 95% CI, 4.0-8.9; P ¼ .016).
Effect on OS
The median OS for the entire cohort was 7.7 months (95% CI,
4.7-10.6 months). The median OS for the 27 patients who devel-
oped any irAEs was 24.3 months (95% CI, 7.2 months to NR)
compared with 5.3 months (95% CI, 3.1-8.3 months) for the 64
patients without irAEs (hazard ratio, 2.75; 95% CI, 1.54-4.92; P <
.001; Figure 2). Patients with irAEs treated with steroids had a
Table 3 Clinical and Laboratory Risk Factors for Development




All patients 27 (30) 64 (70)
Histologic type (nonsquamous,
n ¼ 58)
16 (28) 42 (72) 1.00a
Previous TRT or chest wall RT
(n ¼ 28)
8 (29) 20 (71) .806a
RT after ICI 8 (53) 7 (47) .059b
Smoking history 1.00b
Current/former smoker 24 (30) 57 (70)
Nonsmoker 3 (30) 7 (70.00)
Gender .260a
Male 14 (36) 25 (64)
Female 13 (25) 39 (75)
Inflammatory biomarkers .804a
ALI  18 13 (31) 20 (69) .260a
NLR  5 15 (30) 35 (70) .939a
PLR  237 12 (26) 34 (74) .449a
KRAS mutation (n ¼ 26) 4 (15) 22 (85) .059a
TP53 mutation (n ¼ 37) 7 (19) 30 (81) .063a
Abbreviations: ALI ¼ advanced lung cancer inflammation index; ICI ¼ immune checkpoint
inhibitor; irAE ¼ immune-related adverse event; NLR ¼ neutrophil/lymphocyte ratio; PLR ¼
platelet/lymphocyte ratio; RT ¼ radiotherapy; TRT ¼ thoracic RT.
aAssociation between categorical variables compared using c2 test.
bAssociation between categorical variables compared using Fisher’s exact test.
Figure 1 Swimmer’s Plot of Time to Immune-related Adverse Event (irAE), Duration of Treatment, and Outcome. Patients Who
Developed irAEs > 3 Months Had Improved Overall Survival (OS) Compared With Those Who Had Developed irAEs Within the
First 3 Months (P < .001 With Bonferroni Correction). However, a Landmark Analysis of Patients Still Receiving Treatment at
3 Months Revealed No Differences in Overall Survival Between Patients With and Without irAEs. One Patient (Asterisk) Was
Administered a Different Immunotherapy Treatment (Programmed Cell Death-1) After Stopping Initially and Developed an
irAE
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median OS of 10.3 months (95% CI, 3.7-26.0 months) from the
initiation of ICI therapy, which was not significantly different from
that of those not treated with steroids (median NR; 95% CI, 7.2
months to NR; P ¼ .072). Patients with irAEs who had received
steroids had a significantly shorter OS from the development of
irAEs (median, 8.3 months; 95% CI, 1.2-18.2 months) compared
with those patients who had not received steroids (median, NR;
95% CI, 4.3 months to NR; P ¼ .028). The development of
pneumonitis in 9 patients did not affect OS (P ¼ .34), nor did the
development of colitis (P ¼ .14). In the 7 patients who developed
autoimmune thyroid dysfunction, the median OS was NR (95%
CI, 7.2 months to NR) compared with 6.5 months for patients
without thyroid irAEs (95% CI, 4.4-9.5 months; P ¼ .018;
Figure 2B). The patients’ performance status was associated with
OS (P ¼ .018).
The median OS for the patients who developed irAEs> 3 months
after starting ICI therapy was NR (95% CI, 24.3 months to NR)
compared with 8.0 months (95% CI, 2.4-11.6 months) for those
patients inwhom irAEs occurredwithin the first 3months (P< .001).
Patients who developed irAEs had received ICI treatment longer than
had those who had not developed irAEs (7.2 vs. 1.9 months;
P < .001). In a landmark analysis, OS was not significantly different
for the patients who had received ICI for> 3months without an irAE
compared with either the patients receiving an ICI for > 3 months
with an early irAEs (occurring within 3 months; P ¼ 1.00, with
Bonferroni correction) or patients receiving treatment for> 3months
with late irAEs (occurring after 3 months; P¼ 1.00, with Bonferroni
correction). For the patients receiving treatment for< 3 months, the
median survival for the 41 patients without irAEs was 2.5 months
(95% CI, 1.8-3.6 months) compared with 6.4 months for the 6
patients with irAEs (P < .001, with Bonferroni correction). In the
same landmark analysis, OS was significantly longer for the patients
receiving treatment for > 3 months who developed thyroid irAEs
(median OS, NR; 95% CI, 7.2 months to NR) compared with the
patients without thyroid irAEs (median OS, 16.2 months; 95% CI,
9.5-28.8 months; P ¼ .0296).
Markers of systemic inflammation, including NLR, PLR, and
ALI, were assessed for any association with OS. Patients with an
elevated ALI at treatment initiation had longer median OS (median,
14.9 months; 95% CI, 9.0-19.8 months) compared with patients
with a lower ALI (median, 4.0 months; 95% CI, 2.3-5.5 months;
P < .001). Patients with a baseline elevated NLR (> 5) had a
shorter median OS (median, 4.0 months; 95% CI, 2.3-6.9 months)
compared with those with a lower NLR (median, 11.4 months;
95% CI, 8.7-19.4 months; P ¼ .002). Patients with a lower PLR
(less than the median of 237 in this cohort) had a median OS of 8.9
months (95% CI, 5.1-17.2 months) compared with 5.2 months
(95% CI, 2.6-9.5 months; P ¼ .182) for those with an elevated
PLR at baseline.
Discussion
Although the results of our initial analysis suggested a survival
benefit for patients treated with an ICI who developed irAEs
(Figure 2A), this survival difference was not observed when con-
trolling for the duration of therapy in a landmark analysis at 3
months (Figure 2B). The timing of performing the landmark
analysis at 3 months was chosen because this was the median time of
irAE development. A correlation between clinical benefit and the
development of irAEs has been reported previously. However, the
data have been conflicting regarding the association with OS.9,10,12
We also found that the ALI, NLR, and PLR were not predictive of
the development of irAEs. However, they were of prognostic value
in NSCLC patients who received immunotherapy. We observed an
increase in survival for the patients undergoing RT after beginning
treatment with an ICI. In contrast, patients who had undergone RT
before the initiation of immunotherapy had worse outcomes.
Overall, the irAE rate of 30% was in line with that from previous
studies, and the 10% rate of pneumonitis was slightly greater than
previously reported. Uncommon irAEs, including new-onset auto-
immune diabetes mellitus, thyrotoxicosis, and pancreatic insuffi-
ciency, also occurred. We found no difference in the incidence of
irAEs when stratified by patient gender, age, smoking history, or
tumor histologic type. The greater rate of irAEs in patients treated
in the clinical study might have resulted from the closer monitoring
for, and attribution of, immune toxicities in these patients. We
found that patients who had developed thyroid toxicity during
therapy with an ICI had longer OS than that of patients who had
not, as reported previously.10
We did not observe an increase in either irAEs or pneumonitis in
patients who had received previous RT. The risk factors for radia-
tion pneumonitis have been reported to include the timing and
schedule of RT sessions, the mean lung dose, the target volume and
dose, pre-existing lung disease, and circulating cytokines.22-24 The
risk factors for immunotherapy-related pneumonitis have not been
defined; however, suggestions have included active smoking, which
we were unable to confirm in our study.25 Little is known about
which risk factors increase the likelihood of irAEs overall and
pneumonitis in particular, and what effect irAEs might have on
survival. Case reports have suggested an increased risk of pneumo-
nitis in patients who had previously received TRT26,27; however,
the recent PACIFIC trial (a global study to assess the effects of
MEDI4736 following concurrent chemoradiation in patients with
stage III unresectable non-small cell lung cancer) did not show a






Previous TRT/chest wall RT 5 (18) 23 (82)
No previous TRT 4 (7) 57 (93)
Non-CNS radiation after ICI 3 (20) 12 (80) .165
Heavy smoking history (>50 PYH) 5 (22) 18 (78) 1.00
Inflammatory biomarkers
ALI  18 2 (5) 40 (95) .170
NLR  5 7 (14) 43 (86) .178
PLR  237 4 (9) 42 (91) .739
Abbreviations: ALI ¼ advanced lung cancer inflammation index; CNS ¼ central nervous system;
ICI ¼ immune checkpoint inhibitor; NLR ¼ neutrophil/lymphocyte ratio; PLR ¼ platelet/
lymphocyte ration; PYH ¼ pack-year history; RT ¼ radiotherapy; TRT ¼ thoracic RT.
aAssociation between categorical variables compared using Fisher’s exact test.
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significant increase in severe pneumonitis in patients treated with
durvalumab after concurrent chemoradiation.28 Previous work had
suggested that patients receiving RT before ICI had better out-
comes.29 Evidence has shown a synergistic effect of RT with
immunotherapy, with 1 retrospective analysis from a prospective
study demonstrating an improvement in progression-free survival
and OS in patients treated with pembrolizumab for NSCLC who
had previously received RT.29 However, in our study, previous RT
was associated with worse survival, despite timing between RT and
ICI similar to that in previous studies. This might reflect different
patient populations, because the previous study included patients in
a phase I trial, or might have resulted from the smaller number of
patients with previous RT in our study (28 of 91 patients in our
study compared with 42 of 97 in previous study). Finally, the
improvement in OS seen for patients who had received RT after
starting ICI therapy is interesting; however, the finding should be
interpreted with caution, given the small number of patients
(n ¼ 15) and that patients receiving an ICI who had also received
RT were likely to be those with acceptable performance status or
who had experienced a response to treatment. Preclinical data are
available supporting the role of immunotherapy and RT in shaping
the repertoire of tumor-infiltrating lymphocytes.30 Also, the role of
RT with ICI therapy is being evaluated in NSCLC patients in
several ongoing studies (eg, ClinicalTrials.gov identifier,
NCT02888743).
The association of thyroid dysfunction during immunotherapy
for NSCLC has been described in a previous study, although the
mechanism is not well understood.10 The study investigators
hypothesized that thyroid toxicity during programmed cell death 1/
programmed cell death ligand 1 therapy might occur as a result of
either humoral immunity or an exacerbation of low-level auto-im-
munity. Decreased levels of cytotoxic T-lymphocyteeassociated
protein 4 (CTLA-4)eexpressing T cells have been reported in
pediatric patients with chronic autoimmune thyroiditis.31 Also,
polymorphisms in CTLA-4 have been associated with autoimmune
thyroid disease.32 Whether any relation exists between T-cell
CTLA-4 expression and the development of thyroid dysfunction
during immunotherapy is unknown.
The use of systemic markers of inflammation derived from
routine blood tests to determine prognosis has been well stud-
ied.14,16-18,20,21 One retrospective study of 175 patients found that
an elevated pretreatment NLR was associated with worse survival in
patients with NSCLC treated with nivolumab.21 Additional he-
matologic markers of systemic inflammation include the PLR17,18
Figure 2 Kaplan-Meir Curves for (A) Survival of Patients Who Had Developed Immunotherapy-related Adverse Event(s) (irAE)
(P < .001), Including Specifically Thyroid irAE (C; P [ .018). In a Landmark Analysis Controlling for Duration of Therapy,
Overall Survival Was Not Significantly Different in Patients Who Had Received an Immune Checkpoint Inhibitor (ICI) for > 3
Months With or Without irAEs Overall (B; P [ 1.00, With Bonferroni Correction); However, Thyroid irAEs Remained
Significantly Associated With Survival (D; P [ .0296)
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and the ALI.19,20 A recent retrospective study of 101 patients with
melanoma treated with nivolumab reported that an increased total
white blood cell count and decreased lymphocyte count were
associated with irAEs.33 However, the ability of these tests to predict
the occurrence of irAEs is unknown. In our study, baseline NLR,
ALI, and PLR were not associated with an increased risk of irAE or
pneumonitis. The prognostic value of both NLR and ALI was
confirmed in our study. Although data are available supporting the
use of NLR as a prognostic marker in patients with NSCLC treated
with nivolumab, we are unaware of any data supporting the ALI as a
prognostic biomarker in this patient population.
Our study had several limitations. The sample size was among the
largest in retrospective analyses that have found a clinical benefit in
this patient population. However, our study sample was still suffi-
ciently small that significant findings could have been missed. Also,
our definition of irAEs requiring intervention discounted subclinical
changes that might be useful in predicting the response. More reliable
methods of determining irAEs are needed to better diagnose and
document these events. The outcomes of patients treatedwith steroids
for irAEs might have been because more severe irAEs (ie, pneumo-
nitis, colitis, hepatitis) are commonly treated with steroids and others
are often treated without steroids (ie, thyroid replacement for hypo-
thyroidism). Given the small number of patients in the present study,
the implication of this finding is unclear and should not affect the
decision to treat irAEs with steroids. The presence of thyroid
dysfunction as an early indicator of benefit is attractive because of its
objectivity10 and has been supported by the clinical benefit seen in
patients who developed thyroid dysfunction in our study. Because
most patients were treated with second-line nivolumab, programmed
cell death ligand 1 testing was not routinely performed and, therefore,
was not included in the present analysis. These findings might not be
applicable for patients receiving first-line or combination
immunotherapy.
Conclusion
The present study has added to the current knowledge regarding
the incidence, risk factors, and effect on survival of irAEs in NSCLC
patients. No association between irAEs and survival was observed in
our landmark analysis, although longer OS was observed in patients
with thyroid irAEs, which is encouraging owing to its objectivity.
No clear risk factors for irAEs were identified, and no increased risk
of irAEs was observed in patients who had received RT. The
demonstration of a survival benefit for patients who had received
RT after ICI is encouraging; however, given the small number of
patients and retrospective nature of the study, this finding should be
investigated further in larger prospective clinical trials.
Clinical Practice Points
 Immunotherapy has transformed the treatment of patients with
NSCLC; in general, these treatments have been well tolerated.
 However, irAEs occur and can be serious and even fatal.
 Understanding the incidence, severity, and risk factors for irAEs
will allow for better clinical decisions and management of
NSCLC in patients treated with these agents.
 We have reported that irAEs occurred in 30% of patients treated
with single-agent immunotherapy at our institution.
 These irAEs included well-known toxicities such as pneumonitis
and colitis and more uncommon toxicities such as pancreatic
insufficiency and insulin-dependent diabetes.
 No clear risk factors for irAEs were identified, including previous
RT, tumor histologic type, mutational status, smoking history,
and routine blood test results.
 In our study, previous RT was associated with worse clinical
outcome, and RT after immunotherapy was associated with
improved survival.
 The possible benefit of RT after the initiation of immunotherapy
is being evaluated in several ongoing clinical studies.
 Given the lack of clearly identifiable risk factors for irAEs at
baseline, clinical vigilance and education are of utmost impor-
tance to identify and treat patients who develop irAEs.
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